R&D

News

Specialty meds lift GSK's outlook in Walmsley's swan song

Emma Walmsley's last set of financial results as GSK's chief executive has gone swimmingly, allowing the company to raise its 2025 forecasts.

News

Merck looking to rare disease deals to build health momentum

Germany's Merck KGaA is looking at making further acquisitions to boost its business, with a focus on life sciences and rare diseases.

News

Close up in sepia on Benjamin Franklin face on cash note

Soufflé's tasty $200m raise, and other biofinancings

New biotech financings include nine-figure rounds for Soufflé, Expedition, Arthrosi, and Nilo Therapeutics, with NanoPhoria and TORL not far behind.

R&D

Q3 Clinical trials round-up: July to September 2025

As the third quarter of 2025 draws to a close, the clinical research landscape has been marked by a surge of promising data and regulatory milestones.

News

New £1.2bn science park opens in Oxford

A new £1.2 billion science and technology park was formally opened today in Oxford, in a welcome boost to the UK's life sciences sector.

News

Moderna opens UK facility as drug pricing spat rumbles on

The UK government has celebrated the opening of Moderna's £150m vaccines facility, but storm clouds continue to gather on the issue of drug pricing.

Specialty meds lift GSK's outlook in Walmsley's swan song

Merck looking to rare disease deals to build health momentum

Soufflé's tasty $200m raise, and other biofinancings

Q3 Clinical trials round-up: July to September 2025

New £1.2bn science park opens in Oxford

Moderna opens UK facility as drug pricing spat rumbles on

NHS to offer Wegovy to a million more people in England

Using AI-driven synthetic personas to take your insights fur...

R&D

Editor's Picks